Affiliation:
1. Novokuznetsk State Institute of Postgraduate Medicine
Abstract
Aim — to study of gene polymorphisms affecting the effectiveness of timolol treatment of primary open-angle glaucoma.Patients and Methods. The study included 39 Russian patients (29 women and 10 men) aged 53 to 89 years old with a diagnosis of primary open-angle glaucoma (POAG). Intraocular pressure (IOP) was measured before the start of therapy and after 2 weeks during treatment. Сoefficient of decrease in IOP was calculated in percentage of its initial level (∆D). Patients were genotyped according to the polymorphic loci MMP1-160insG, MMP12A-82G, TIMP1C536T, ADRB1Arg389Gly, ADRB1Ser49Gly, NAT2Lys268Arg, GSTP1Ile105Val using the corresponding SNP-express reagent kits (NPF Lytech, Moscow).Results. No effect of MMP12A-82G, TIMP1C536T, ADRB1Arg389Gly, NAT2Lys268Arg polymorphisms on efficiency of reduction of IOP under action of thymolol in “best” eyes was revealed. The carriage of a homozygous genotype GSTP1Ile105Ile resulted in the best ophthalmic hypotensive effect of a timolol (∆D ≥ 20 %), which probability was 5.63 times higher in comparison with ∆D < 20 %. In the “worst” eyes, the association of carriage of a combination of wild genotypes GSTP1Ile105Ile×NAT2Lys268Lys with the best response of patients to timolol was revealed. The ophthalmic hypotensive effect of 10 ≤ ∆D < 20 % in such carriers was more than 11 times more likely than ∆D < 10 %.Conclusion. The carriage of the wild genotype GSTP1Ile105Ile determines the best ophthalmic hypotensive effect of timolol and can be a prognostic marker for the effective treatment of patients with POAG. The combination of wild genotypes GSTP1Ile105Ile×NAT2Lys268Lys can contribute to the better therapeutic effect of timolol, and mutant ones can prevent it.
Publisher
PE Polunina Elizareta Gennadievna
Reference23 articles.
1. National Glaucoma Guide: for practitioners. Eds. prof. E.A. Egorov, prof. Yu.S. Astakhov, prof. V.P. Yerichev. Moscow: GEOTAR-Media, 2015 (In Russ.).
2. Egorov E.A., Erichev V.P., Onishchenko A.L., Petrov S.Yu., Kuroedov A.V., Antonov A.A., Vitkov A.A. Systemic risk factors for developing of primary open-angle glaucoma. Russian Medical Journal. Clinical Ophthalmology = Rossiyskiy medicinskiy zhurnal. Klinicheskaya oftal’mologiya. 2018;3:140–145 (In Russ.). DOI: 10.21689/2311-7729-2018-18-3-140-145
3. Onishchenko A.L., Likhacheva I.G., Tkachev V.A., Plastinina S.L. Study of factors of insufficient adherence to the treatment of patients with primary glaucoma. National Journal glaucoma = Natsional’nyi zhurnal glaucoma. 2009;3:32−35 (In Russ.).
4. Onishchenko A.L., Kolbasko A.V., Isakov I.N., Shirina M.A. The study of the causes of medical inertness in the treatment of patients with glaucoma. Annals of Ophthalmology = Vestnik oftal’mologii. 2013;6:58–61 (In Russ.).
5. Weinreb R.N., Liebermann J. Drug treatment of glaucoma. 7th Consensus of the World Glaucoma Association. Saint-Peterborg: Publishing house N-L, 2014 (In Russ.).